The Indian/South African Proposal For a WTO Waiver On IP For COVID-19 Related Health Products – What It Means? 14/10/2020 Ellen 't Hoen A sweeping proposal by India and South Africa to suspend the protection of intellectual property (IP) related to COVID-19 health products is set to come before the The World Trade Organization’s TRIPS Council this week. The closed door discussion lays the groundwork for what could prove to be the most significant public debate over […] Continue reading -> Urgent Action Needed To End Tuberculosis By 2030, Concludes WHO’s Global Tuberculosis Report 14/10/2020 Svĕt Lustig Vijay The world must take urgent action to end the global tuberculosis epidemic by 2030, especially as the pandemic threatens to unwind hard-won progress made in past decades, concluded the WHO’s 2020 Global Tuberculosis Report on Wednesday. While the WHO European region is on track to achieve key 2020 targets, the rest of the world has […] Continue reading -> Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> US Food and Drug Administration Issues New Rules Likely To Delay COVID-19 Vaccine Approval Until After Presidential Election 07/10/2020 Elaine Ruth Fletcher Acting on the advice of experts, the United States Food and Drug Administration on Tuesday issued new safety-focused guidelines for approval of new COVID-19 vaccines, that would almost certainly delay their emergency approval until after the November Presidential elections. Just hours after the rules were issued, United States President Donald Trump accused the FDA of […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> Posts navigation Older postsNewer posts
Urgent Action Needed To End Tuberculosis By 2030, Concludes WHO’s Global Tuberculosis Report 14/10/2020 Svĕt Lustig Vijay The world must take urgent action to end the global tuberculosis epidemic by 2030, especially as the pandemic threatens to unwind hard-won progress made in past decades, concluded the WHO’s 2020 Global Tuberculosis Report on Wednesday. While the WHO European region is on track to achieve key 2020 targets, the rest of the world has […] Continue reading -> Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> US Food and Drug Administration Issues New Rules Likely To Delay COVID-19 Vaccine Approval Until After Presidential Election 07/10/2020 Elaine Ruth Fletcher Acting on the advice of experts, the United States Food and Drug Administration on Tuesday issued new safety-focused guidelines for approval of new COVID-19 vaccines, that would almost certainly delay their emergency approval until after the November Presidential elections. Just hours after the rules were issued, United States President Donald Trump accused the FDA of […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> Posts navigation Older postsNewer posts
Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> US Food and Drug Administration Issues New Rules Likely To Delay COVID-19 Vaccine Approval Until After Presidential Election 07/10/2020 Elaine Ruth Fletcher Acting on the advice of experts, the United States Food and Drug Administration on Tuesday issued new safety-focused guidelines for approval of new COVID-19 vaccines, that would almost certainly delay their emergency approval until after the November Presidential elections. Just hours after the rules were issued, United States President Donald Trump accused the FDA of […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> Posts navigation Older postsNewer posts
US Food and Drug Administration Issues New Rules Likely To Delay COVID-19 Vaccine Approval Until After Presidential Election 07/10/2020 Elaine Ruth Fletcher Acting on the advice of experts, the United States Food and Drug Administration on Tuesday issued new safety-focused guidelines for approval of new COVID-19 vaccines, that would almost certainly delay their emergency approval until after the November Presidential elections. Just hours after the rules were issued, United States President Donald Trump accused the FDA of […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> Posts navigation Older postsNewer posts
Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> Posts navigation Older postsNewer posts
WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> Posts navigation Older postsNewer posts
Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> Posts navigation Older postsNewer posts
WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> Posts navigation Older postsNewer posts
Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> Posts navigation Older postsNewer posts
Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> Posts navigation Older postsNewer posts